Abstract
Background
To investigate the relationship between the position of bilateral STN-DBS location of active contacts and the clinical efficacy of STN-DBS on motor symptoms in Parkinson’s disease (PD) patients.
Methods
Retrospectively analyze the clinical data of 57 patients with PD who underwent bilateral STN-DBS from March 2018 to December 2018. Unified Parkinson’s Disease Rating Scale-Part III (UPDRS-III) score, levodopa equivalent day dose (LEDD), Parkinson’s Disease Quality of Life Scale (PDQ-39) before operation and within 6 months after operation, determine the location of activated contacts and volume of tissue activated (VTA) in the Montreal Neurological Institute (MNI) space, and analyze their correlation with the improvement rate of motor symptoms (UPDRS-III score improvement rate).
Results
After 6 months of follow up, the UPDRS-III scores of 57 patients (Med-off) were improved by 55.4 ± 18.9% (P<0.001) compared with that before operation. The improvement rate of PDQ-39 scores [(47.4 ± 23.2)%, (P < 0.001)] and the reduction rate of LEDD [(40.1 ± 24.3)%, (P < 0.01)] at 6 months postoperation were positively correlated with the improvement rate of motor symptoms (Med-off)(PDQ-39:r = 0.461, P<0.001; LEDD: r = 0.354, P = 0.007), the improvement rate of UPDRS-III (Med-off) and the Z-axis coordinate of the active contact in the MNI space were positively correlated (left side: r = 0.349,P = 0.008;right side: r = 0.369,P = 0.005). In the MNI space, there was no correlation between the UPDRS-III scores improvement rate (Med-off) at 6 months after operation and bilateral VTA in the STN motor subregion, STN associative subregion and STN limbic subregion of the active electrode contacts of 57 patients (all P > 0.05). At 6 months after surgery, the difference between the Z-axis coordinate in the different improvement rate subgroups(<25, 25 to 50%, and>50%) in the MNI space was statistically significant (left side: P = 0.030; right side: P = 0.024). In the MNI space, there was no statistically significant difference between the groups in the VTA of the electrode active contacts (all P > 0.05).
Conclusion
STN-DBS can improve the motor symptoms of PD patients and improve the quality of life. The closer the stimulation is to the STN dorsolateral sensorimotor area, the higher the DBS is to improve the motor symptoms of PD patients.
Keywords: Parkinson’s disease, Deep brain stimulation, Subthalamic nucleus, Motor symptom, Active contacts, Volume of tissue activated
Background
PD is a neurodegenerative disease common in middle-aged and elderly people, and deep brain stimulation (DBS) is an accepted treatment at an advanced stage [1, 2]. Studies have shown that subthalamic nucleus (STN) DBS can improve dyskinesias and improve the quality of life (QOL) in PD patients [3–6]. Every now, the STN is publicly preconceived the target of choice [4]. Studies have shown that the improvement in postoperative motor improvement depends in particular on age and disease duration [6] and preoperative response to dopaminergic drugs [7], this makes it critical to screen for the right DBS candidates. In the past, optimizing the parameters of DBS postoperative programming has been proved to be an important factor to improve the therapeutic effect on PD. However, the most important factors that determine the improvement of DBS on motor symptoms are precise stimulation targets and effective stimulation volume, that is, the position of the electrode active contact in STN and VTA [8, 9]. The purpose of this study was to investigate the relationship between the position of bilateral STN-DBS location of active contacts and the clinical efficacy of STN-DBS on motor symptoms in PD patients.
Methods
Between March and December 2018, a total of 57 subjects were hospitalized at the Department of Neurosurgery of the Beijing Tiantan Hospital affiliated to Capital Medical University, the First Hospital of Hebei Medical University for optimizing a previously performed STN-DBS.
The 57 patients were selected from partial database data, not all patients at the same time. All patients received bilateral stimulation. All patients and their families (spouse or children) have informed consent and signed an informed consent form, the study was approved by the Medical Ethics Committee of Beijing Tiantan Hospital affiliated to Capital Medical University, and the ethics committee approved this form of proxy consent.
Patient selection
Evaluations were executed by neurologists specialized in movement disorders. Patients with advanced idiopathic PD diagnosed based on the diagnostic criteria for PD in China (2016 edition) and PD surgical treatment evaluation criteria [10]. All patients underwent preoperative testing and analyzed the levodopa challenge test (LCT), confirming that levodopa response needs to be improved by at least 30%, and those who had complete imaging and scoring data and could follow up regularly. Morphologic MRI is performed to exclude patients with severe cerebral atrophy, ischemic disease, and severe cognitive impairment and mental illness.
Surgical procedures
Surgical procedures were carried out as previously described [11, 12]. An image fusion procedure (3 T MRI and 1.5 T MRI) is commonly used by our group. The Leksell stereotactic frame was placed (Elekta Instruments AB, Stockholm, Sweden) on the day of surgery. A contrast-enhanced full head computerized tomography (CT) scan was carried out and the images were fused with a preoperative frameless MRI including the new planning. All images were imported into Surgiplan (Elekta Instrument AB) and were reformatted. The coordinates of the target and the entrance trajectory were defined by directly visualizing the STN on the image fusion of a CT and preOP MRI, based on MRI T2 DESS (double-echo at steady state). Microelectrode recording (MER) (FHC, Frederic Haer Company, Boston, Massachusetts) and stimulation with neurological response examination were performed. The electrodes were implanted under local anesthesia. The STN target coordinates were 2–3 mm posterior to the mid-intercommissural point (MCP), 11–13 mm lateral to AC-PC and 4–6 mm below the AC-PC [12]. The optimal track (best effects on motor symptoms with the lowest stimulation intensity and largest safety margin) was chosen for each side. Quadripolar electrodes (model L301, PINS Medical, Beijing, China or model 3389 s, Medtronic, Minneapolis, MN, USA), were bilaterally implanted into the STN under local anesthesia in one session. Macro stimulation was used to re-verify target accuracy, symptom improvement and side effects. At the end of the surgical procedure, a implantable pulse generator (IPG) (G102 or G102R (PINS Medical) or Activa RC or Activa PC (Medtronic)) was implanted under general anesthesia on the same day. Postoperative CT scans was performed after surgery on the same day to exclude cerebral hemorrhage and to verify the exact location of the electrodes by merging with the preoperative MR images.
Stimulation programming
One month after the operation, the IPG was turned on and programmed [13]. DBS was activated with 60 μs,130 Hz and 1.5–2.0 V as standard pulse parameters. The contacts on each electrode were tested and the best stimulation parameters, when the patient achieved satisfactory improvement with minimal side effects were selected. In subsequent follow-up, a regular adjustment of stimulation settings (Voltage) and the levodopa equivalent day dose (LEDD) until optimal control of symptoms was established. Some patients use bipolar or double negative stimulation.
Clinical evaluation
The study with four assessments, one baseline or screening assessment before surgery, one at 1 month after surgery, one at 3 months after surgery and finally one at 6 months after surgery. Demographic characteristics (age, gender, age at onset, duration of the disease) and disease severity, assessed by the UPDRS-III (3rd edition), ranging from 0 (no impairment) to 108 (maximum impairment),were recorded for all patients. The Hoehn-Yahr scale was used for disease staging. LEDD calculated based on a previously published algorithm combining dopamine agonist daily dose with levodopa daily dose. Quality of life (QOL) was assessed using PDQ-39, ranging from 0 (no impairment) to 124 (maximum impairment). Postoperative motor symptom improvement rate (%) = (preoperative UPDRS-IIIscores-postoperative UPDRS-III scores)/preoperative UPDRS-III scores× 100%. The drug improvement rate was the result of the preoperative levodopa challenge test. The drug improvement rate (%) = (UPDRS-III baseline scores before taking the drug-UPDRS-III lowest scores after taking the drug) / UPDRS-III baseline scores before taking the drug× 100%.Berg Balance Scale score improvement rate (%) = (postoperative BBS score-preoperative BBS score) / preoperative BBS score × 100%. FOG-Q score improvement rate (%) = (preoperative FOG-Q score-postoperative FOG-Q score) / preoperative FOG-Q score × 100%.
The position of DBS location of active contacts and VTA estimation
(1) DBS electrode location [8, 14]: Use Lead-DBS software (developed by the Department of Movement Disorders, Department of Neuromedicine, Berlin Charity University, Germany) to locate the DBS electrodes. (2) VTA: The volume of STN in the Montreal Neurological Institute (MNI) standard space is defined by the DISTAL atlas, and the VTA is calculated after verifying the electrode position [15, 16].
Statistical analyses
All statistical analyses were performed using SPSS 25.0 (v25.0.0.0,SPSS Inc., Chicago/Illinois/USA). Continuous variables that followed, or approximately followed, a normal distribution are presented as mean ± standard deviation( ±s). Continuous variables that did not follow a normal distribution are presented as the median (M) and interquartile range (IQR). The Friedman test was used for continuous variables that did not follow a normal distribution and the Kruskal-Wallis rank sum test was used for comparison between multiple groups. Categorical variables are presented as constituent ratios or percentages, and chi-square tests were used for comparison between groups. Through the Pearson correlation analysize the relationship between the improvement rate of UPDRS-III scores, LEDD change rate, the improvement rate of PDQ-39 scores, the VTA, the coordinates of the electrode activate contacts, the VTA, and the distance from the electrode activate contacts to the STN motor subregion, associative subregion, and limbic subregion were discussed. Pearson correlation analysis was used to determine which factors are associated with improvement of anxiety and depression after DBS. The statistical significance threshold was fixed at P < 0.05.
Results
Patient population
According to the above criteria, a total of 57 patients were included. Among them, 34 males (59.6%) and 23 females (40.4%); mean age was (64.1 ± 8.0) (46–82); mean onset age (54.0 ± 8.1) (35–73); mean disease duration (10.1 ± 5.1) (2–23). The LEDD of 57 patients before surgery was (866.3 ± 357.0) (125–1625) mg/d; the preoperative Hoehn-Yahr stage was (2.9 ± 0.3) (2–4).
Clinical outcomes
DBS on PD patients with motor symptoms and its correlation analysis results
Comparisons between preoperative and postoperative (1, 3 and 6 months after surgery) clinical stages are summarized in Table 1 and Fig. 1. After 6 months of follow up, the UPDRS-III scores of 57 patients (Med-off) were improved by 55.4 ± 18.9% (P<0.001) compared with preoperatively. The improvement rate of PDQ-39 score [(47.4 ± 23.2)%] and the reduction rate of LEDD [(40.1 ± 24.3)%] at 6 months after surgery.
Table 1.
Comparison of preoperative and postoperative clinical state [M (IQR)]
| Time | Medication off | Medication on | |||||
|---|---|---|---|---|---|---|---|
| UPDRS-III (0 ~ 108) | BBS (0 ~ 56) | UPDRS-III (0 ~ 108) | BBS (0 ~ 56) | LEDD (mg) | PDQ-39 (0 ~ 124) | FOG-Q | |
| Preoperative | 60.0 (23) | 44 (11) | 26.2 (23) | 52 (7) | 831 (453) | 49 (38) | 14 (12) |
| Postoperative | |||||||
| 1 month | 35.0 (22) | 48 (11) | 15.0 (16) | 53 (5) | – | – | 9 (12) |
| 3 month | 31.5 (12) | 48 (10) | 13.0 (13) | 53 (5) | 550 (357.5) | 34 (25) | 9 (12) |
| 6 month | 31.0 (17) | 48 (12) | 12.0 (11) | 54 (5) | 475 (220.5) | 23 (20) | 9 (10) |
| Total P | <0.001 | 0.084 | <0.001 | 0.058 | <0.001 | <0.001 | 0.068 |
| χ2 | 109.966 | 35.705 | 74.042 | 29.351 | 62.000 | 104.246 | 7.131 |
| P1 | <0.001 | – | <0.001 | – | – | – | – |
| P2 | <0.001 | – | <0.001 | – | < 0.010 | < 0.010 | – |
| P3 | <0.001 | – | <0.001 | – | < 0.010 | < 0.010 | – |
P1 value is the result of comparison between 1 month and preoperative, P2 value is the result of comparison between 3 months and preoperative, P3 value is the result of comparison between 6 months and preoperative; STN-DBS Subthalamic nucleus - deep brain stimulation, UPDRS-III Unified Parkinson’s Disease Rating ScaleIII, BBS Berg Balance Scale, LEDD Levodopa equivalent dose, PDQ-39 39-Item Parkinson’s Disease Questionnaire, FOG-Q Freeze of gait questionnaire; except LEDD unit is mg, all other index units are points
Fig. 1.
Comparison of preoperative and postoperative HAMA and HAMD scores: a, b UPDRS-III scores (Med-OFF) were improved by 55.4% follow-up 6 months after surgery; c, d UPDRS-III scores (Med-OFF) were improved by 44.6% follow-up 6 months after surgery; e, f LEDD was decreased to 40.1%.(G-H)PDQ-39 scores were improved by 47.4%; (*:P < 0.05;**:P < 0.001); (STN-DBS: subthalamic nucleus - deep brain stimulation, UPDRS-III: Unified Parkinson’s Disease Rating ScaleIII, BBS: Berg Balance Scale, LEDD: Levodopa equivalent dose, PDQ-39: 39-Item Parkinson’s Disease Questionnaire) [Baseline: baseline; FU1: 1 month after surgery; FU2: 3 months after surgery; FU3: 6 months after surgery]
The improvement rate of motor symptoms (UPDRS-III scores) (Med-off) in 57 patients 6 months after operation was positively correlated with the reduction rate of LEDD (r = 0.262, P = 0.049) (Fig. 2a). At 6 months after surgery, the improvement rate of the PDQ39 scores of 57 patients was positively correlated with the improvement rate of motor symptoms (Med-off) (r = 0.461, P < 0.001) (Fig. 2b); the reduction rate of LEDD was positively correlated with the improvement rate of motor symptoms (Med-off) (r = 0.354, P = 0.007) (Fig. 2c).
Fig. 2.
Correlation between the improvement rate of DBS motor symptoms and drug improvement rate (the reduction rate of LEDD), the improvement rate of PDQ39 scores and the decement of LEDD and the improvement rate of motor symptoms: 6 months after surgery, 57 PD patients after STN-DBS. a DBS motor symptoms improvement rate (UPDRS-III scores in Med off) was positively correlated with drug improvement rate. b The improvement rate of PDQ39 scores was positively correlated with the improvement rate motor symptoms. c The decrease of LEDD is positively correlated with the improvement rate of motor symptoms . (STN-DBS: subthalamic nucleus-deep brain stimulation, UPDRS-III: Unified Parkinson’s Disease Rating Scale III, BBS: Berg Balance Scale, LEDD: Levodopa daily equivalent dose, PDQ-39: 39-Item Parkinson’s Disease Questionnaire)
Post-operative DBS setting
Of the 57 patients, 3 (5.3%) required bipolar stimulation, 2 (3.5%) required bipolar negative stimulation, and the remaining 52 patients (91.2%) all received unipolar stimulation. The stimulation parameters of 57 patients: the voltage is (2.04 ± 0.57) V (0.8 ~ 3.0 V), the pulse width is (64 ± 10) μs (50 ~ 90 μs); the frequency is (135 ± 14) Hz (110 ~ 175 Hz).
The active contact locations in MNI space and its relationship with the improvement rate of motor symptoms in PD patients
The electrode active contacts: left side: 10 cases with contact 1, 42 cases with contact 2, 5 cases with contact 3; right side: 10 cases with contact 1, 35 cases with contact 2, 11 cases with contact 3 and 1 cases with contact 4(Contact 1 refers to the most ventral contact and contact 4 the most dorsal one).
The mean coordinates of active contacts in MNI and AC-PC (anterior commissure- posterior commissure) of 57 patients (Table 2). Six months after surgery, the improvement rate of UPDRS-III (Med-off) and the active contact in MNI the Z-axis of the position is positively correlated (right side: r = 0.369,P = 0.005;left side: r = 0.349,P = 0.008) (Figs. 3a.b and 4a.b). This indicates that the higher the z-axis (closer to the dorsal STN), the higher the DBS UPDRS-III improvement rate.
In the MNI space, the mean distance from the active contact to the STN motor subregion, STN associative subregion, STN limbic subregion [M (IQR)] was: ①left side: 0.1 (0.5) mm, 0.8 (1.3) mm, 1.0 (1.0) mm.②right side: 0.2 (0.6) mm, 1.1 (1.1) mm, 0.8 (1.4) mm; In the MNI space, there was no correlation between the improvement rate (Med-off) of the UPDRS-III scores in 57 patients 6 months after operation and the electrode active contact to the STN motor subregion (left side: r = − 0.152,P = 0.259;right side: r = − 0.202,P = 0.652), STN associative subregion (left side: r = − 0.057,P = 0.671;right side: r = − 0.219, P = 0.101) and STN limbic subregion (left side: r = 0.100, P = 0.461;right side: r = 0.241, P = 0.071).
In the MNI space, the active contact VTA in the STN motor subregion, STN associative subregion, STN limbic subregion were: ①left side: 18.5 (7.5) mm3, 13.7 (8.4) mm3, 14.7 (8.2) mm3;②right side: 16.2 (6.3) mm3, 8.3 (9.9) mm3, 14.3 (9.0) mm3. In the MNI space, there was no correlation between the improvement rate (Med-off) of the UPDRS-III scores in 57 patients 6 months after operation and the VTA in the STN motor subregion (left side: r = 0.051,P = 0.705;right side: r = 0.090,P = 0.507),in STN associative subregion (left side: r = − 0.113,P = 0.403;right side: r = 0.205,P = 0.127),in STN limbic subregion (left side: r = − 0.108, P = 0.424;right side: r = − 0.236,P = 0.077).
Table 2.
57 patients cartesian coordinates of active DBS contacts (mm)
| Axis | Active contact [mm] in MNI | Active contact [mm] in AC-PC | ||||||
|---|---|---|---|---|---|---|---|---|
| Left | Right | Left | Right | |||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| X | −11.5 | 1.1 | 12.0 | 1.1 | 11.6 | 1.5 | 12.0 | 1.2 |
| Y | −13.5 | 1.4 | −13.5 | 1.3 | −1.7 | 1.5 | −1.6 | 1.4 |
| Z | −8.2 | 1.0 | −8.3 | 1.5 | −3.9 | 1.0 | −4.0 | 1.1 |
STN-DBS Subthalamic nucleus deep brain stimulation, MNI Montreal Neurological Institute, AC-PC Anterior commissure- posterior commissure
Fig. 3.
Correlation between the improvement rate of the UPDRS-III scores and the Z-axis coordinate of the active contacts in the MNI space: a, b The improvement rate of the UPDRS-III scores (Med-off) and the Z-axis of the active contacts in the MNI space are positively correlated (right side: r = 0.369, P = 0.005; left side: r = 0.349, P = 0.008) (UPDRS-III:Unified Parkinson’s Disease Rating ScaleIII; MNI:Montreal Neurological Institute)
Table 4.
Comparison results of active contact coordinates in AC-PC space in different motor symptom improvement rate groups [M (IQR), mm]
| Group | Number of cases | Left | Right | ||||
|---|---|---|---|---|---|---|---|
| X | Y | Z | X | Y | Z | ||
| Improvement rates < 25% group | 5 | −10.8 (1.6) | −1.7 (3.2) | −4.5 (0.4) | 11.5 (1.6) | −1.9 (2.0) | −4.8 (1.2) |
| Improvement rates 25–50% group | 11 | −11.7 (3.2) | − 1.5 (2.5) | − 4.3 (1.9) | 11.6 (2.4) | −1.9 (1.2) | − 4.3 (1.5) |
| Improvement rates > 50% group | 41 | −11.7 (2.1) | − 1.8 (1.6) | −3.7 (1.6) | 12.3 (1.8) | − 1.7 (2.1) | − 3.8 (1.2) |
| Kruskal-Wallis χ2 | 1.888 | 0.529 | 1.970 | 1.039 | 0.194 | 3.847 | |
| P | 0.389 | 0.768 | 0.373 | 0.595 | 0.908 | 0.146 | |
Comparison of DBS active contacts position and VTA in different groups with different improvement rates of motor symptoms
Improvement rates< 25% group:5 cases (8.8%), improvement rates 25–50% group:11 cases (19.3%), improvement rates> 50% group:41 cases (71.9%).
The position of the DBS active contacts in groups (Fig. 4a b): In the MNI space, the difference between in the Z-axis coordinate is statistically significant (left side: P = 0.030;right side: P = 0.024), while on both sides in the X, Y-axis, there was no statistically significant difference between them (all P > 0.05, Table 3); In AC-PC space, there was no statistically significant difference between the three groups on the X,Y,Z-axis coordinate (all P > 0.05, Table 4), In the MNI space, there was no statistically significant difference between the distances from the active contacts to the STN subregion (all P > 0.05, Table 5).
The VTA of the electrode active contacts in the MNI space of each group: In the MNI space, there was no statistically significant difference between the groups in the VTA of the electrode active contacts (all P > 0.05, Table 6, Fig. 4c.d).
Fig. 4.
3D illustration of all active electrode contacts: a, b. Electrode position of 57 PD patients (a):Electrode position, posterior view;(b):active contact,posterior view; (The blue dots represent group I (DBS improvement rates < 25%), the white dots represent group II (DBS improvement rates between 25 and 50%) and the red dots represent group III (DBS improvement rates> 50%).). c relationship between volume of tissue activated (VTA) in STN. (Yellow: STN. Red: red nucleus. Green: Gpi. Blue: Gpe.). d relationship between volume of tissue activated (VTA) in STN subregions. (Dark yellow nucleus: STN motor subregion. Blue nucleus: STN associative subregion. Pale yellow nucleus: STN limbic subregion. Red nucleus: red nucleus)
Table 3.
Comparison results of active contact coordinates in MNI space in different motor symptom improvement rate groups [M (IQR), mm]
| Group | Number of cases | Left | Right | ||||
|---|---|---|---|---|---|---|---|
| X | Y | Z | X | Y | Z | ||
| Improvement rates < 25% group | 5 | −12.1 (1.9) | −14.0 (2.6) | −9.4 (1.0) | 12.1 (1.9) | −14.7 (2.6) | −9.3 (1.5) |
| Improvement rates 25–50% group | 11 | −11.1 (1.9) | − 13.2 (2.6) | −8.1 (1.3) | 11.3 (1.9) | − 13.5 (1.9) | −8.4 (2.1) |
| Improvement rates > 50% group | 41 | −11.6 (1.2) | − 13.4 (1.7) | −7.9 (1.1) | 12.1 (1.6) | − 13.6 (2.2) | −7.8 (1.2) |
| Kruskal-Wallis χ2 | 2.366 | 0.461 | 7.036 | 1.200 | 2.261 | 7.455 | |
| P | 0.306 | 0.794 | 0.030 | 0.549 | 0.323 | 0.024 | |
Table 5.
The mean distance of different motor symptom improvement rate groups in the MNI space from the active contacts to the STN subregion [M (IQR), mm]
| Group | Number of cases | Left | Right | ||||
|---|---|---|---|---|---|---|---|
| STN motor subregion | STN associative subregion | STN limbic subregion | STN motor subregion | STN associative subregion | STN limbic subregion | ||
| Improvement rates < 25% group | 5 | 0.2 (1.2) | 1.4 (1.1) | 1.5 (1.5) | 0.4 (1.2) | 1.7 (1.4) | 0.4 (1.0) |
| Improvement rates 25–50% group | 11 | 0.1 (1.4) | 0.7 (1.4) | 1.9 (0.9) | 0.1 (0.6) | 0.6 (1.2) | 0.5 (0.8) |
| Improvement rates > 50% group | 41 | 0.1 (0.4) | 0.8 (1.2) | 0.9 (1.1) | 0.2 (0.5) | 1.1 (1.1) | 0.9 (1.5) |
| Kruskal-Wallisχ2 | 0.251 | 1.693 | 0.255 | 2.200 | 4.158 | 2.908 | |
| P | 0.882 | 0.429 | 0.881 | 0.333 | 0.128 | 0.234 | |
Table 6.
The mean VTA of different motor symptom improvement rate groups in the MNI space [M (IQR), mm3]
| Group | Number of cases | Left | Right | ||||
|---|---|---|---|---|---|---|---|
| STN motor subregion | STN associative subregion | STN limbic subregion | STN motor subregion | STN associative subregion | STN limbic subregion | ||
| Improvement rates < 25% group | 5 | 12.9 (16.6) | 9.1 (13.6) | 10.6 (9.5) | 15.6 (5.3) | 5.6 (7.4) | 15.7 (8.8) |
| Improvement rates 25–50% group | 11 | 18.2 (6.3) | 15.5 (8.0) | 15.6 (10.0) | 16.2 (8.0) | 12.1 (9.9) | 15.2 (5.1) |
| Improvement rates > 50% group | 41 | 20.1 (13.0) | 13.4 (8.3) | 14.7 (8.2) | 17.1 (10.8) | 8.6 (9.9) | 12.6 (10.1) |
| Kruskal-Wallis χ2 | 1.129 | 1.544 | 0.140 | 0.958 | 3.945 | 3.613 | |
| P | 0.569 | 0.462 | 0.933 | 0.619 | 0.139 | 0.164 | |
Discussion
STN-DBS has a good effect on PD motor symptoms [17]. In our study, compared to the baseline, STN-DBS improved UPDRS-III scores and major motor function, both Med-on and Med-off postoperatively. These results demonstrate that DBS has a unique advantage in relieving motor symptoms, the patient’s scores in Med-on / Stim-on postoperatively were lower than the scores in Med-on preoperatively; it has a better effect on improving motor symptoms of PD patients. In addition, the most effective contacts were dorsal contacts, this is similar to reports that the contact selection is dorsal to the STN [18]. In our study, we observed a large reduction in LEDD 6 months after operation, LEDD reduction was more than 40% compared to the preoperative dose, which was related to the improvement rate of motor symptoms in DBS (UPDRS-III scores reduced by 55.4%), Which was consistent with a 19 to 80.7% reduction in drug dose and 53–92% improvement in dyskinesia scores [19, 20]. The LEDD reduction rate was positively correlated with the improvement rate of motor symptoms (r = 0.354, P = 0.007). We think that the better the effect of DBS on improving patients’ motor symptoms, the more LEDD is reduced. Through the PDQ-39 assessment, the QOL (quality of Life) of our patients improved by 47.4% overall, which also proved the good effect of STN-DBS. This result is consistent with previous studies, with an improvement in quality of life from 30.2 to 50.6% [21]. In our study the PDQ39 improvement rate was positively correlated with the improvement rate of motor symptoms, (r = 0.461,P < 0.001),the better the effect of DBS on improving motor symptoms, the better the QOL of patients.
Active contact location
We observed that electrode active contacts in STN-DBS patients were mainly distributed in dorsolateral STN. As we all know, the dorsolateral STN is involved in motor function, and the dorsolateral STN serves as the target region for STN-DBS in PD patients [22]. Stimulation of the dorsolateral STN (sensory motor function area) is expected to disrupt pathological neuronal motor activity or afferent fibers and improve clinical symptoms. In our study, the improvement rate of UPDRS-III scores of more than 50% was basically concentrated in the dorsolateral part of STN, the active contacts location of patients with the improvement rate of UPDRS-III scores 25 to 50% was more concentrated in the middle part of STN, the active contacts position of patients with the improvement rate of UPDRS-III scores less than 25% was more concentrated in the ventral part of STN. After statistical analysis, it was found that only the z-axis coordinate in MNI was significantly different. Optimal location of DBS stimulation within STN: the dorsolateral part of STN is traditionally considered to represent the optimal location of the motor region and stimulation [23]. So far, this part can only be confirmed by intraoperative electrophysiology, which shows an increase in βoscillation activity [24]. The results of our study support the conclusion that the position of the electrode active contacts help to judge the motor effect of STN-DBS. This study found that the improvement rate of motor symptoms is related to the reduction of LEDD, but the correlation coefficient is only 0.262, which needs further research.
.VTA
The effect of programmed parameters (voltage, pulse width, frequency) on the efficacy of DBS surgery is critical. The therapeutic effect is not only on the single contact, but also on the larger electric field range than the contact. Therefore, Andreas Horn’s method of VAT calculation [15] was used to analyze the stimulation parameters of postoperative active contacts and calculate the correlation between the VTA and the UPDRS motor scores. We used the VAT calculation to evaluate the clinical efficacy of STN-DBS in PD patients, although the difference between the VTA of the electrode activate contacts in the MNI space of each group was not statistically significant (all P > 0.05), however, it was found that the higher the VTA of the electrode activate contact of the patient in the STN motor subregion, the higher the improvement of motor symptoms. The difference is not statistically significant and may be related to the sample size of this study. It may be due to the individual differences in the anatomical structure of the target area, due to the difference in the myelin sheath and diameter of the axons in the brain tissue, the response to stimulation may be different, the conductivity and dielectric value of the tissue are different, and the transmission of excitability and excitement may be affected. Influences. In addition, impedance, tissue capacitance and other factors will cause the difference of results.
Limitations
(1) It is a retrospective analysis of a small sample of 57 patients, the sample is small; (2) The average follow-up period is half a year and the time is short; (3) The treatment mechanism of DBS in this study has not been clarified. Despite these limitations, our results further confirm that DBS electrode active contacts located dorsolateral to STN can achieve better clinical efficacy and are proportional to the percentage of VTA located in STN motor subregion. Therefore, direct functional evidence supports only a mild dorsal- ventral gradient of STN DBS motor effects, and does not support strict dorsal- ventral dissociation.
Conclusion
STN-DBS can improve the motor symptoms of PD patients and improve the quality of life. The closer the stimulation is to the STN dorsolateral sensorimotor area, the higher the DBS is to improve the motor symptoms of PD patients.
Acknowledgements
We are grateful to all the patients recruited for this study. We thank the medical ethics committee of IRB of Beijing Tiantan Hospital Affiliated to Capital Medical University for the approval of our study. Special thanks to the research methods provided by the Department of Neurosurgery, Zhujiang Hospital, Southern Medical University.
Abbreviations
- PD
Parkinson’s disease
- STN
Subthalamic nucleus
- DBS
Deep brain stimulation
- UPDRS-III
Unified Parkinson’s Disease Rating Scale-Part III
- LEDD
Levodopa equivalent day dose
- QOL
Quality of life
- PDQ-39
39-Item Parkinson’s Disease Questionnaire
- VTA
Volume of tissue activated
- MNI
Montreal Neurological Institute
- LCT
Levodopa challenge test
- CT
Computerized tomography
- MER
Microelectrode recording
- Med-off
Medication-off
- Med-on
Medication-on
- MCP
Mid-intercommissural point
- AC-PC
Anterior Commissure- Posterior Commissure
- IPG
Implantable pulse generator
Authors’ contributions
Study concept and design: FG M. Data collection: F Z, SY F, N W, CL H, P L, LF X. Analysis and interpretation: F Z, F W, SY F, WG L. Drafting of the manuscript: F Z. Critical revision of the manuscript: JG Z, FG M. Study supervision: FG M, JG Z. F Z was a major contributor in writing the manuscript. The authors read and approved the manuscript.
Funding
This study was funded by Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (XMLX201833, ZYLX201820), The Key Research and Development Program of Ningxia (2018BFG02007) and National Natural Science Foundation of China (81971070). The funder had no role in the study design, data collection, or analysis, the decision to publish or the preparation of the manuscript.
Availability of data and materials
The datasets used and/or analyzed during the current study not publicly available due to privacy reasons of patients, but are available from the corresponding author on reasonable request.
Declarations
Ethics approval and consent to participate
All authors clearly consented to and approved this manuscript. The study strictly followed the ethical principles set out in the “Declaration of Helsinki “. All patients and their families (spouse or children) have informed consent and signed an informed consent form, the study was approved by the Medical Ethics Committee of Beijing Tiantan Hospital affiliated to Capital Medical University, and the ethics committee approved this form of proxy consent.
Consent for publication
Not applicable.
Competing interests
There are no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Jianguo Zhang, Email: zjguo73@126.com.
Fangang Meng, Email: fgmeng@ccmu.edu.cn.
References
- 1.Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896–912. doi: 10.1016/S0140-6736(14)61393-3. [DOI] [PubMed] [Google Scholar]
- 2.Parsons TD, Rogers SA, Braaten AJ, et al. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol. 2006;5(7):578–588. doi: 10.1016/S1474-4422(06)70475-6. [DOI] [PubMed] [Google Scholar]
- 3.Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 1998;339(16):1105–1111. doi: 10.1056/NEJM199810153391603. [DOI] [PubMed] [Google Scholar]
- 4.Benazzouz A, Hallett M. Mechanism of action of deep brain stimulation. Neurology. 2000;55(Suppl 6):S13–S16. doi: 10.1007/s100720070058. [DOI] [PubMed] [Google Scholar]
- 5.Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006;355(9):896–908. doi: 10.1056/NEJMoa060281. [DOI] [PubMed] [Google Scholar]
- 6.Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord. 2006;21(Suppl 14):S290–S304. doi: 10.1002/mds.20962. [DOI] [PubMed] [Google Scholar]
- 7.Caire F, Ranoux D, Guehl D, et al. A systematic review of studies on anatomical position of electrode contacts used for chronic subthalamic stimulation in Parkinson's disease. Acta Neurochir. 2013;155(9):1647–1654. doi: 10.1007/s00701-013-1782-1. [DOI] [PubMed] [Google Scholar]
- 8.Horn A, Reich M, Vorwerk J, et al. Connectivity predicts deep brain stimulation outcome in parkinson’s disease. Ann Neurol. 2017;82(1):67–78. doi: 10.1002/ana.24974. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Jahanshahi M, Obeso I, Rothwell JC, et al. A fronto-striato-subthalamic-pallidal network for goal-directed and habitual inhibition. Nat Rev Neurosci. 2015;16(12):719–732. doi: 10.1038/nrn4038. [DOI] [PubMed] [Google Scholar]
- 10.Lewis SJ, Foltynie T, Blackwell AD, et al. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry. 2005;76(3):343–348. doi: 10.1136/jnnp.2003.033530. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ostrem JL, Marks WJ, Volz MM, et al. Pallidal deep brain stimulation in patients with cranial-cervical dystonia (Meige syndrome) Mov Disord. 2007;22(13):1885–1891. doi: 10.1002/mds.21580. [DOI] [PubMed] [Google Scholar]
- 12.Zhang F, Meng FG. Research progress of functional anatomy of subthalamic nucleus. Chin J Neurosurg. 2020;36(4):426–429. doi: 10.3760/cma.j.cn112050-20190729-00333. [DOI] [Google Scholar]
- 13.Horn A, Li N, Dembek TA, et al. Lead-DBS v2: towards a comprehensive pipeline for deep brain stimulation imaging. Neuroimage. 2019;184:293–316. doi: 10.1016/j.neuroimage.2018.08.068. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Husch A, V PM, Gemmar P, et al. PaCER - a fully automated method for electrode trajectory and contact reconstruction in deep brain stimulation. Neuroimage Clin. 2018;17:80–89. doi: 10.1016/j.nicl.2017.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Rabie A, Metman LV, Fakhry M, et al. Improvement of advanced parkinson's disease manifestations with deep brain stimulation of the subthalamic nucleus:a single institution experience. Brain Sci. 2016;6(4):58. doi: 10.3390/brainsci6040058. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Yao C, Horn A, Li N, et al. Post-operative electrode location and clinical efficacy of subthalamic nucleus deep brain stimulation in Meige syndrome. Parkinsonism Relat Disord. 2019;58:40–45. doi: 10.1016/j.parkreldis.2018.05.014. [DOI] [PubMed] [Google Scholar]
- 17.Castrioto A, Lozano AM, Poon YY, et al. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol. 2011;68(12):1550–1556. doi: 10.1001/archneurol.2011.182. [DOI] [PubMed] [Google Scholar]
- 18.Chen DL, Zhang XM, Nie P, et al. Programming parameter analysis of subthalamic deep brain stimulation for the treatment of Parkinson's disease. Chin J Neurosurg. 2019;35(12):1210–1215. doi: 10.3760/cma.j.issn.1001-2346.2019.12.005. [DOI] [Google Scholar]
- 19.Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 2003;349(20):1925–1934. doi: 10.1056/NEJMoa035275. [DOI] [PubMed] [Google Scholar]
- 20.Chen YS, Li Q, Li JG, et al. Influencing factors of effect of subthalamic nucleus deep brain stimulation on Parkinson's disease. Chin J Neurosurg. 2018;34(4):374–378. doi: 10.3760/cma.j.issn.1001-2346.2018.04.011. [DOI] [Google Scholar]
- 21.Martínez-Martín P, Valldeoriola F, Tolosa E, et al. Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. Mov Disord. 2002;17(2):372–377. doi: 10.1002/mds.10044. [DOI] [PubMed] [Google Scholar]
- 22.Guo S, Zhuang P, Hallett M, et al. Subthalamic deep brain stimulation for Parkinson's disease: correlation between locations of oscillatory activity and optimal site of stimulation. Parkinsonism Relat Disord. 2013;19(1):109–114. doi: 10.1016/j.parkreldis.2012.08.005. [DOI] [PubMed] [Google Scholar]
- 23.Zaidel A, Spivak A, Grieb B, et al. Subthalamic span of beta oscillations predicts deep brain stimulation efficacy for patients with Parkinson's disease. Brain. 2010;133(Pt 7):2007–2021. doi: 10.1093/brain/awq144. [DOI] [PubMed] [Google Scholar]
- 24.Gross RE, Krack P, Rodriguez-Oroz MC, et al. Electrophysiological mapping for the implantation of deep brain stimulators for Parkinson's disease and tremor. Mov Disord. 2006;21(14):259–283. doi: 10.1002/mds.20960. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The datasets used and/or analyzed during the current study not publicly available due to privacy reasons of patients, but are available from the corresponding author on reasonable request.